CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension

Farmville, NC. August 7, 2017 – CMP Pharma today announced that the US Food and Drug Administration (FDA) has granted final approval of the company’s New Drug Application (NDA) for CaroSpir (Spironolactone Oral Suspension, 25 mg/5mL), the first...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news